Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial operations. Mercier was an executive at Bristol-Myers Squibb Co. (NYSE:BMY) for 10 years, most recently as president of the pharma's U.S. and large markets division.

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) promoted Kevin Fitzgerald from head of research to SVP, CSO...